内美通联合促性腺激素释放激素激动剂治疗子宫内膜异位症的临床研究

目的 研究观察内美通联合促性腺激素释放激素激动剂( GnRH-a)治疗子宫内膜异位症的临床疗效.方法 将我院收治的80例子宫内膜异位症患者随机均分为两组:观察组给予内美通联合GnRH-a治疗,对照组给予GnRH-a治疗.观察两组患者的症状、体征和盆腔超声检查等,并进行分析.结果 观察组中有36例完全治愈,3例缓解,1例复发；对照组有29例完全治愈,9例缓解,2例复发.两组比较差异有统计学意义(P＜ 0.05).服药后的毒副作用在阴道出血、ALT升高方面差异具有统计学意义(P＜0.05).观察组用药前后FSH、LH、E2均下降,各项指标差异具有统计学意义(P＜0.05)；对照组的差异无统计学意义(P＞ 0.05).结论 内美通联合GnRH-a治疗子宫内膜异位症可以有效的提高治疗效果、降低复发率和药物的不良反应,是一种有较高价值的方法.

Gestrinone combined with gonadotropin-releasing hormone agonist for endometriosis

Objective To observe the clinical efficacy of gonadotropin-releasing hormone agonist （ GnRH-a ） combined with gestrinone in the treatment of endometriosis. Methods 80 patients with endometriosis were randomly assigned to receive gestrinone combined with GnRH-a （ study group ）, or GnRH-a alone （ control group ）. The symptoms, signs, and findings of pelvic ultrasonic examination were observed and analyzed. Results In the study group, 36 patients were cured, 3 had symptom relief, and one developed relapse, whereas 29 patients were cured, 9 had symptom relief, and 2 occurred relapse in the control group, with a significant difference （ P〈 0.05 ）. The rate of adverse reactions including vaginal bleeding and ALT elevation differed significantly between the two groups （ P〈 0.05 ）. As compared with the baselines, levels of FSH, LH, and E2 declined significantly in the study group （ P 〈 0.05 ） but did not change significantly in the control group （ P 〉 0.05 ）. Conclusions Gestrinone combined with GnRH-a can effectively improve the therapeutic effeet and can reduce the rates of relapse rate and adverse reactions. It ias a valuable therapy.